EA200900537A1 - Высокоаффинный сайт связывания hgfr и способы идентификации его антагонистов - Google Patents

Высокоаффинный сайт связывания hgfr и способы идентификации его антагонистов

Info

Publication number
EA200900537A1
EA200900537A1 EA200900537A EA200900537A EA200900537A1 EA 200900537 A1 EA200900537 A1 EA 200900537A1 EA 200900537 A EA200900537 A EA 200900537A EA 200900537 A EA200900537 A EA 200900537A EA 200900537 A1 EA200900537 A1 EA 200900537A1
Authority
EA
Eurasian Patent Office
Prior art keywords
affince
hgfr
antagonists
identification
methods
Prior art date
Application number
EA200900537A
Other languages
English (en)
Other versions
EA017863B1 (ru
Inventor
Паоло Мария Комольо
Паоло Карминати
Паоло Микьели
Кристина Базилико
Original Assignee
Метерезис Транслейшнл Ресерч Са
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Метерезис Транслейшнл Ресерч Са filed Critical Метерезис Транслейшнл Ресерч Са
Publication of EA200900537A1 publication Critical patent/EA200900537A1/ru
Publication of EA017863B1 publication Critical patent/EA017863B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Применение полинуклеотида, кодирующего, по меньшей мере, внеклеточные домены IPT-3 и IPT-4 рецептора фактора роста гепатоцитов, или полипептида, включающего, по меньшей мере, внеклеточные домены IPT-3 и IPT-4 рецептора фактора роста гепатоцитов, для скрининга и/или разработки фармакологически активных агентов, применяемых при лечении рака, предпочтительно рака, характеризующегося разбалансировкой рецептора фактора роста гепатоцитов.
EA200900537A 2008-05-14 2009-05-13 Высокоаффинный сайт связывания hgfr и способы идентификации его антагонистов EA017863B1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08103958 2008-05-14

Publications (2)

Publication Number Publication Date
EA200900537A1 true EA200900537A1 (ru) 2009-12-30
EA017863B1 EA017863B1 (ru) 2013-03-29

Family

ID=40984839

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200900537A EA017863B1 (ru) 2008-05-14 2009-05-13 Высокоаффинный сайт связывания hgfr и способы идентификации его антагонистов

Country Status (18)

Country Link
US (4) US8404453B2 (ru)
EP (1) EP2119448B1 (ru)
JP (1) JP5623027B2 (ru)
KR (1) KR101509263B1 (ru)
AT (1) ATE513556T1 (ru)
BR (1) BRPI0901502A2 (ru)
CA (1) CA2665958C (ru)
CY (1) CY1111853T1 (ru)
DK (1) DK2119448T3 (ru)
EA (1) EA017863B1 (ru)
ES (1) ES2368603T3 (ru)
HR (1) HRP20110643T1 (ru)
IL (1) IL198545A0 (ru)
MX (1) MX2009005049A (ru)
PL (1) PL2119448T3 (ru)
PT (1) PT2119448E (ru)
SG (1) SG157312A1 (ru)
SI (1) SI2119448T1 (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL198545A0 (en) 2008-05-14 2011-07-31 Metheresis Translational Res Sa High affinity binding site of hgfr and methods for identification of antagonists thereof
EP3165538A1 (en) 2010-11-03 2017-05-10 Argen-X Nv Anti c-met antibodies
GB2504139B (en) 2012-07-20 2014-12-31 Argen X Bv Antibodies to highly conserved targets produced by the immunisation of Camelidae species
EP2773660A2 (en) 2011-11-03 2014-09-10 Argen-X B.V. Chimeric human-camel antigens and their use
WO2013079973A1 (en) * 2011-12-02 2013-06-06 Di Cara Danielle Marie Antibodies against hgf - receptor and uses
US11035860B2 (en) 2014-11-20 2021-06-15 Stichting Katholieke Universiteit Auto-active and intracellular mutant of MET
EP3519440A4 (en) 2016-09-29 2020-03-25 Mitsubishi Tanabe Pharma Corporation MONOCLONAL CMET BINDERS, ACTIVE SUBSTANCE CONJUGATES AND USES THEREOF
CN113567685B (zh) * 2021-09-26 2022-05-17 瑞博奥(广州)生物科技股份有限公司 基于核酸适配体探针的hgfr识别方法及检测hgfr的试剂盒
CN116121255A (zh) * 2022-12-20 2023-05-16 中国科学院基础医学与肿瘤研究所(筹) 一种结合hgfr蛋白的核酸适配体及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3293823B2 (ja) * 1991-05-10 2002-06-17 フアルマシア・エ・アツプジヨン・エツセ・ピー・アー 肝細胞成長因子（ｈｇｆ）レセプターの部分切除形態
US5686292A (en) * 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
AU2760602A (en) 2001-03-23 2002-09-26 Agouron Pharmaceuticals, Inc. Catalytic domains of the human hepatocyte growth factor receptor tyrosine kinase, and materials and methods for identification of inhibitors thereof
WO2007036945A2 (en) 2005-09-30 2007-04-05 Compugen Ltd. Hepatocyte growth factor receptor splice variants and methods of using same
CN1922208A (zh) 2003-12-11 2007-02-28 健泰科生物技术公司 用于抑制c－met二聚化及活化的方法和组合物
US20060069019A1 (en) 2004-05-06 2006-03-30 Genentech, Inc. Crystal structure of the complex of hepatocyte growth factor beta chain with Met receptor and methods of use
US20060008844A1 (en) * 2004-06-17 2006-01-12 Avidia Research Institute c-Met kinase binding proteins
EP1911459B1 (en) * 2005-07-28 2015-12-02 AnGes MG, Inc. Lymphangiogenesis promoter
ES2368864T3 (es) * 2006-02-06 2011-11-23 Metheresis Translational Research Sa Anticuerpos monoclonales anti-met, sus fragmentos y vectores para el tratamiento de tumores y productos correspondientes.
IL198545A0 (en) 2008-05-14 2011-07-31 Metheresis Translational Res Sa High affinity binding site of hgfr and methods for identification of antagonists thereof

Also Published As

Publication number Publication date
EP2119448B1 (en) 2011-06-22
US8404453B2 (en) 2013-03-26
KR101509263B1 (ko) 2015-04-06
MX2009005049A (es) 2009-12-18
PL2119448T3 (pl) 2011-11-30
BRPI0901502A2 (pt) 2010-01-26
JP5623027B2 (ja) 2014-11-12
EP2119448A1 (en) 2009-11-18
SG157312A1 (en) 2009-12-29
SI2119448T1 (sl) 2012-02-29
US20130183690A1 (en) 2013-07-18
DK2119448T3 (da) 2011-09-26
US20120108789A1 (en) 2012-05-03
PT2119448E (pt) 2011-09-27
US9121854B2 (en) 2015-09-01
US20120115219A1 (en) 2012-05-10
EA017863B1 (ru) 2013-03-29
HRP20110643T1 (hr) 2011-10-31
CY1111853T1 (el) 2015-11-04
ATE513556T1 (de) 2011-07-15
US20090298079A1 (en) 2009-12-03
US9310377B2 (en) 2016-04-12
KR20090118846A (ko) 2009-11-18
CA2665958C (en) 2014-01-07
AU2009201893A1 (en) 2009-12-03
CA2665958A1 (en) 2009-11-14
IL198545A0 (en) 2011-07-31
JP2009291191A (ja) 2009-12-17
ES2368603T3 (es) 2011-11-18

Similar Documents

Publication Publication Date Title
PT2119448E (pt) Local de elevada afinidade de ligação no hgfr e processos para a identificação dos antagonistas correspondentes
EA201300330A1 (ru) Антагонисты активина-actriia и их применение для стимулирования роста кости
EA200801172A1 (ru) Лиганды, имеющие специфичность связывания в отношении рецептора эпидермального фактора роста (egfr) и/или сосудистого эндотелиального фактора роста (vegf), и способы их применения
CR10147A (es) "ligandos que tienen especificidad de enlace para vegf y/o egfr y métodos de uso de los mismos"
LTPA2017011I1 (lt) Antikūnas prieš PDGFR-alfa, skirtas naudoti auglių gydymui
UA95768C2 (ru) Антагонисты мускариновых рецепторов ацетилхолина
DE602005002853D1 (de) Vorrichtungen zum Reparieren von lebendem Gewebe
CY2025024I2 (el) Βελτιωμενα επιλεκτικα πρωτοϊνιδιων αντισωματα και η χρηση αυτων
ATE554785T1 (de) Modifizierte fgf-21 polypeptide und ihre verwendung
ZA200908470B (en) Polypeptides,antibody variable domains and antagonists
DK1771474T3 (da) Inhibitorer af angiopoitin-like 4 protein, kombinationer og anvendelser deraf
IL201399A0 (en) Polypeptides, antibody variable domains and antagonists
EP2134854A4 (en) TREATMENT PROCEDURE USING EGFR ANTIBODIES AND SRC INHIBITORS AND ASSOCIATED FORMULATIONS
EP1850797A4 (en) METHOD, MATERIALS AND DEVICE FOR TREATING BONE AND OTHER WOVEN FABRICS
DE602006007698D1 (de) Maschine zur Zubereitung von Getränken mit Funktionsvorrichtung und Fußaufbau
EA201500316A1 (ru) Антагонисты толл-подобного рецептора 3
FI20050770L (fi) Todentaminen turvakäytännön yhteydessä
IL212333A0 (en) Polypeptides, antibody variable domains & antagonists
ATE417045T1 (de) Substituierte diazaspiroä5.5üundecanderivate und deren verwendung als neurokininantagonisten
EA200900562A1 (ru) Способ лечения расстройства, связанного с ангиогенезом
DE602005010204D1 (de) Baumaschine mit drehbarem Oberwagen
DE602006018166D1 (de) Polyrotaxanhaltige lösung und verwendung davon
ATE483460T1 (de) Amino-oxo-indolyliden-verbindungen zur verwendung in der behandlung von juckender kopfhaut
DE502005002812D1 (de) Zungennadel
EA200700949A1 (ru) Фармацевтические композиции, основанные на антагонистах nk2, для применения в педиатрической практике

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU